Personalis, Inc. (NASDAQ:PSNL) Receives Average Recommendation of “Moderate Buy” from Brokerages

Personalis, Inc. (NASDAQ:PSNL) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $12.50.

A number of equities analysts recently issued reports on the stock. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. BTIG Research dropped their target price on shares of Personalis from $13.00 to $11.00 and set a “buy” rating on the stock in a research note on Monday, May 11th. TD Cowen reiterated a “buy” rating on shares of Personalis in a report on Wednesday. Morgan Stanley raised their price target on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Tuesday, April 21st.

Personalis Stock Down 1.2%

PSNL stock opened at $15.39 on Tuesday. The business has a 50 day moving average of $10.94 and a 200 day moving average of $8.90. The firm has a market cap of $1.61 billion, a PE ratio of -15.09 and a beta of 2.24. Personalis has a twelve month low of $3.84 and a twelve month high of $16.39.

Personalis (NASDAQ:PSNL) last released its earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%.The company had revenue of $15.47 million during the quarter, compared to the consensus estimate of $14.48 million. On average, research analysts expect that Personalis will post -1.07 earnings per share for the current fiscal year.

Insider Buying and Selling at Personalis

In other news, CEO Christopher M. Hall sold 100,000 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,558,668.88. This represents a 29.76% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 4,982 shares of the stock in a transaction on Monday, June 29th. The shares were sold at an average price of $14.00, for a total value of $69,748.00. Following the sale, the chief financial officer directly owned 198,833 shares in the company, valued at $2,783,662. This trade represents a 2.44% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 435,032 shares of company stock worth $5,599,929. Company insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Personalis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Royal Bank of Canada grew its stake in shares of Personalis by 3.2% in the first quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock worth $275,000 after acquiring an additional 2,395 shares during the period. Dynamic Technology Lab Private Ltd lifted its position in Personalis by 75.6% during the first quarter. Dynamic Technology Lab Private Ltd now owns 76,729 shares of the company’s stock valued at $269,000 after purchasing an additional 33,044 shares during the period. Goldman Sachs Group Inc. boosted its holdings in Personalis by 55.7% in the first quarter. Goldman Sachs Group Inc. now owns 284,426 shares of the company’s stock worth $998,000 after purchasing an additional 101,706 shares during the last quarter. Focus Partners Wealth purchased a new stake in Personalis in the first quarter worth approximately $47,000. Finally, JPMorgan Chase & Co. grew its position in Personalis by 505.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 29,491 shares of the company’s stock worth $193,000 after purchasing an additional 24,621 shares during the period. Institutional investors own 61.91% of the company’s stock.

Personalis Company Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.